L-DOPA modifies the antidepressant-like effects of reboxetine and fluoxetine in rats

Neuropharmacology

Volumn 67, Issue , 2013, Pages 349-358

  Miguelez, C ^a   Berrocoso, E ^b,c   Mico, J A ^b,c   Ugedo, L ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b UNIVERSITY OF CÁDIZ   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

Dorsal raphe nucleus; Fluoxetine; L DOPA; Locus coeruleus; Reboxetine; Single unit extracellular recording

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; FLUOXETINE; REBOXETINE;

ADRENERGIC TRANSMISSION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; FORCED SWIMMING TEST; LOCUS CERULEUS; MALE; NONHUMAN; NORADRENERGIC NERVE; PRIORITY JOURNAL; RAT; SENSITIVITY ANALYSIS; SEROTONINERGIC NERVE; SEROTONINERGIC TRANSMISSION; SINGLE DRUG DOSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DRUG THERAPY, COMBINATION; FLUOXETINE; LEVODOPA; LOCUS COERULEUS; MALE; MORPHOLINES; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 84873348519     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.11.016     Document Type: Article

References (99)

1. A. Alachkar, J.M. Brotchie, and O.T. Jones Binding of dopamine and 3-methoxytyramine as L-DOPA metabolites to human alpha(2)-adrenergic and dopaminergic receptors Neurosci. Res. 67 2010 245 249
2. C. Alba-Delgado, M. Llorca-Torralba, I. Horrillo, J.E. Ortega, J.A. Mico, P. Sanchez-Blazquez, J.J. Meana, and E. Berrocoso Chronic pain leads to concomitant noradrenergic impairment and mood disorders Biol. Psychiatr. 73 2013 54 62
3. R. Arai, N. Karasawa, M. Geffard, T. Nagatsu, and I. Nagatsu Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase Brain Res. 667 1994 295 299
4. R. Arai, N. Karasawa, M. Geffard, and I. Nagatsu L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study Neurosci. Lett. 195 1995 195 198
5. R. Arai, N. Karasawa, and I. Nagatsu Aromatic L-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study Brain Res. 706 1996 177 179
6. R. Arai, N. Karasawa, and I. Nagatsu Dopamine produced from L-DOPA is degraded by endogenous monoamine oxidase in neurons of the dorsal raphe nucleus of the rat: an immunohistochemical study Brain Res. 722 1996 181 184
7. B.A. Baldo, R.A. Daniel, C.W. Berridge, and A.E. Kelley Overlapping distributions of orexin/hypocretin- and dopamine-beta-hydroxylase immunoreactive fibers in rat brain regions mediating arousal, motivation, and stress J. Comp. Neurol. 464 2003 220 237
8. J.M. Baraban, and G.K. Aghajanian Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonists Neuropharmacology 19 1980 355 363
9. J.M. Baraban, and G.K. Aghajanian Suppression of serotonergic neuronal firing by alpha-adrenoceptor antagonists: evidence against GABA mediation Eur. J. Pharmacol. 66 1980 287 294
10. G. Bartholini, M. Da Prada, and A. Pletscher Decrease of cerebral 5-hydroxytryptamine by 3,4-dihydroxyphenylalanine after inhibition of extracerebral decarboxylase J. Pharm. Pharmacol. 20 1968 228 229
11. M. Bauer, M. Adli, T. Bschor, M. Pilhatsch, A. Pfennig, J. Sasse, R. Schmid, and U. Lewitzka Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants Neuropsychobiology 62 2010 36 42
12. C. Bishop, J.A. George, W. Buchta, A.A. Goldenberg, M. Mohamed, S.O. Dickinson, S. Eissa, and K.L. Eskow Jaunarajs Serotonin transporter inhibition attenuates L-DOPA-induced dyskinesia without compromising L-DOPA efficacy in hemi-parkinsonian rats Eur. J. Neurosci. 36 2012 2839 2848
13. P. Blier Resiliency of monoaminergic systems: the 80% rule and its relevance to drug development J. Psychopharmacol. 22 2008 587 589
14. A. Borah, and K.P. Mohanakumar Long-term L-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats Cell. Mol. Neurobiol. 27 2007 985 996
15. M.L. Bouthenet, M.P. Martres, N. Sales, and J.C. Schwartz A detailed mapping of dopamine D-2 receptors in rat central nervous system by autoradiography with [125I]iodosulpride Neuroscience 20 1987 117 155
16. L. Bravo, J.A. Mico, R. Rey-Brea, B. Perez-Nievas, J.C. Leza, and E. Berrocoso Depressive-like states heighten the aversion to painful stimuli in a rat model of comorbid chronic pain and depression Anesthesiology 117 2012 613 625
17. M. Carta, T. Carlsson, D. Kirik, and A. Bjorklund Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats Brain 130 2007 1819 1833
18. P. Cassano, L. Lattanzi, F. Soldani, S. Navari, G. Battistini, A. Gemignani, and G.B. Cassano Pramipexole in treatment-resistant depression: an extended follow-up Depress Anxiety 20 2004 131 138
19. P. Cassano, L. Lattanzi, M. Fava, S. Navari, G. Battistini, M. Abelli, and G.B. Cassano Ropinirole in treatment-resistant depression: a 16-week pilot study Can. J. Psychiatr. 50 2005 357 360
20. J.M. Cedarbaum, and G.K. Aghajanian Noradrenergic neurons of the locus coeruleus: inhibition by epinephrine and activation by the alpha-antagonist piperoxane Brain Res. 112 1976 413 419
21. H.W. Clement, D. Gemsa, and W. Wesemann Serotonin-norepinephrine interactions: a voltammetric study on the effect of serotonin receptor stimulation followed in the N. raphe dorsalis and the Locus coeruleus of the rat J. Neural Transm. Gen. Sect. 88 1992 11 23
22. J.W. Commissiong, and E.M. Sedgwick Depletion of 5-HT by L-DOPA in spinal cord and brainstem of rat Life Sci. 25 1979 83 86
23. T.J. Connor, P. Kelliher, A. Harkin, J.P. Kelly, and B.E. Leonard Reboxetine attenuates forced swim test-induced behavioural and neurochemical alterations in the rat Eur. J. Pharmacol. 379 1999 125 133
24. J. Constantinidis, G. Bartholini, R. Tissot, and A. Pletscher Accumulation of dopamine in the parenchyma after decarboxylase inhibition in the capillaries of brain Experientia 24 1968 130 131
25. J.F. Cryan, R.J. Valentino, and I. Lucki Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test Neurosci. Biobehav. Rev. 29 2005 547 569
26. O. Curet, C. De Montigny, and P. Blier Effect of desipramine and amphetamine on noradrenergic neurotransmission: electrophysiological studies in the rat brain Eur. J. Pharmacol. 221 1992 59 70
27. J.F. Czachura, and K. Rasmussen Effects of acute and chronic administration of fluoxetine on the activity of serotonergic neurons in the dorsal raphe nucleus of the rat Naunyn Schmiedebergs Arch. Pharmacol. 362 2000 266 275
28. G.S. Dawe, K.D. Huff, J.L. Vandergriff, T. Sharp, M.J. O'Neill, and K. Rasmussen Olanzapine activates the rat locus coeruleus: in vivo electrophysiology and c-Fos immunoreactivity Biol. Psychiatr. 50 2001 510 520
29. A. Dekeyne, A. Gobert, L. Iob, L. Cistarelli, C. Melon, and M.J. Millan Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats Psychopharmacology (Berl). 158 2001 213 218
30. M.J. Detke, M. Rickels, and I. Lucki Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants Psychopharmacology (Berl). 121 1995 66 72
31. M.J. Detke, J. Johnson, and I. Lucki Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression Exp. Clin. Psychopharmacol. 5 1997 107 112
32. P. Devoto, G. Flore, L. Pani, and G.L. Gessa Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex Mol. Psychiatr. 6 2001 657 664
33. P. Devoto, G. Flore, L. Pira, G. Longu, and G.L. Gessa Alpha2-adrenoceptor mediated co-release of dopamine and noradrenaline from noradrenergic neurons in the cerebral cortex J. Neurochem. 88 2004 1003 1009
34. P. Devoto, G. Flore, P. Saba, M. Fa, and G.L. Gessa Co-release of noradrenaline and dopamine in the cerebral cortex elicited by single train and repeated train stimulation of the locus coeruleus BMC Neurosci. 6 2005 31
35. S. Dhillon, L.P. Yang, and M.P. Curran Bupropion: a review of its use in the management of major depressive disorder Drugs 68 2008 653 689
36. M. El Mansari, B.P. Guiard, O. Chernoloz, R. Ghanbari, N. Katz, and P. Blier Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder CNS Neurosci. Ther. 16 2010 e1 17
37. A. Eltayb, M.L. Wadenberg, and T.H. Svensson Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa Biol. Psychiatr. 58 2005 337 343
38. G. Engstrom, C. Alling, K. Blennow, G. Regnell, and L. Traskman-Bendz Reduced cerebrospinal HVA concentrations and HVA/5-HIAA ratios in suicide attempters. Monoamine metabolites in 120 suicide attempters and 47 controls Eur. Neuropsychopharmacol. 9 1999 399 405
39. G.M. Everett, and J.W. Borcherding L-DOPA: effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice Science 168 1970 847 850
40. S. Ferre, R. Cortes, and F. Artigas Dopaminergic regulation of the serotonergic raphe-striatal pathway: microdialysis studies in freely moving rats J. Neurosci. 14 1994 4839 4846
41. N.H. Garcia, T.J. Berndt, G.M. Tyce, and F.G. Knox Chronic oral L-DOPA increases dopamine and decreases serotonin excretions Am. J. Physiol. 277 1999 R1476 R1480
42. J.C. Garratt, F. Crespi, R. Mason, and C.A. Marsden Effects of idazoxan on dorsal raphe 5-hydroxytryptamine neuronal function Eur. J. Pharmacol. 193 1991 87 93
43. L. Grandoso, J. Pineda, and L. Ugedo Comparative study of the effects of desipramine and reboxetine on locus coeruleus neurons in rat brain slices Neuropharmacology 46 2004 815 823
44. B.P. Guiard, M. El Mansari, Z. Merali, and P. Blier Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions Int. J. Neuropsychopharmacol. 2008 1 15
45. M.B. Hamner, and B.I. Diamond Plasma dopamine and norepinephrine correlations with psychomotor retardation, anxiety, and depression in non-psychotic depressed patients: a pilot study Psychiatr. Res. 64 1996 209 211
46. A. Harkin, J.P. Kelly, M. McNamara, T.J. Connor, K. Dredge, A. Redmond, and B.E. Leonard Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression Eur. J. Pharmacol. 364 1999 123 132
47. A.M. Hemmerle, J.P. Herman, and K.B. Seroogy Stress, depression and Parkinson's disease Exp. Neurol. 233 2012 79 86
48. A.S. Horn Structure-activity relations for the inhibition of catecholamine uptake into synaptosomes from noradrenaline and dopaminergic neurones in rat brain homogenates Br. J. Pharmacol. 47 1973 332 338
49. T. Inoue, Y. Kitaichi, T. Masui, S. Nakagawa, S. Boku, T. Tanaka, K. Suzuki, Y. Nakato, R. Usui, and T. Koyama Pramipexole for stage 2 treatment-resistant major depression: an open study Prog. Neuropsychopharmacol. Biol. Psychiatr. 34 2010 1446 1449
50. S. Kapur, and J.J. Mann Role of the dopaminergic system in depression Biol. Psychiatr. 32 1992 1 17
51. R.C. Kessler, K.R. Merikangas, and P.S. Wang Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century Annu. Rev. Clin. Psychol. 3 2007 137 158
52. L.G. Kirby, and I. Lucki Interaction between the forced swimming test and fluoxetine treatment on extracellular 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in the rat J. Pharmacol. Exp. Ther. 282 1997 967 976
53. K. Kitahama, I. Nagatsu, M. Geffard, and T. Maeda Distribution of dopamine-immunoreactive fibers in the rat brainstem J. Chem. Neuroanat. 18 2000 1 9
54. Y. Kitaichi, T. Inoue, S. Nakagawa, T. Izumi, and T. Koyama Effect of co-administration of lithium and reboxetine on extracellular monoamine concentrations in rats Eur. J. Pharmacol. 489 2004 187 191
55. V. Klimek, J.E. Schenck, H. Han, C.A. Stockmeier, and G.A. Ordway Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study Biol. Psychiatr. 52 2002 740 748
56. S. Koch, K.W. Perry, D.L. Nelson, R.G. Conway, P.G. Threlkeld, and F.P. Bymaster R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study Neuropsychopharmacology 27 2002 949 959
57. G. Lambert, M. Johansson, H. Agren, and P. Friberg Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders Arch. Gen. Psychiatr. 57 2000 787 793
58. A. Lieberman Depression in Parkinson's disease-a review Acta Neurol. Scand. 113 2006 1 8
59. Y. Lin, D. Quartermain, A.J. Dunn, D. Weinshenker, and E.A. Stone Possible dopaminergic stimulation of locus coeruleus alpha1-adrenoceptors involved in behavioral activation Synapse 62 2008 516 523
60. H.S. Lindgren, D.R. Andersson, S. Lagerkvist, H. Nissbrandt, and M.A. Cenci L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia J. Neurochem. 112 2010 1465 1476
61. L. Linner, C. Wiker, L. Arborelius, M. Schalling, and T.H. Svensson Selective noradrenaline reuptake inhibition enhances serotonergic neuronal activity and transmitter release in the rat forebrain J. Neural Transm. 111 2004 127 139
62. D.A. Loeffler, P.A. LeWitt, P.L. Juneau, D.M. Camp, L.A. Arnold, and K. Hyland Time-dependent effects of levodopa on regional brain dopamine metabolism and lipid peroxidation Brain Res. Bull. 47 1998 663 667
63. A. Mansour, J.H. Meador-Woodruff, J.R. Bunzow, O. Civelli, H. Akil, and S.J. Watson Localization of dopamine D2 receptor mRNA and D1 and D2 receptor binding in the rat brain and pituitary: an in situ hybridization-receptor autoradiographic analysis J. Neurosci. 10 1990 2587 2600
64. A.A. Mansour, D.M. Babstock, J.H. Penney, G.M. Martin, J.H. McLean, and C.W. Harley Novel objects in a holeboard probe the role of the locus coeruleus in curiosity: support for two modes of attention in the rat Behav. Neurosci. 117 2003 621 631
65. R. Martin-Ruiz, L. Ugedo, M.A. Honrubia, G. Mengod, and F. Artigas Control of serotonergic neurons in rat brain by dopaminergic receptors outside the dorsal raphe nucleus J. Neurochem. 77 2001 762 775
66. N.B. Mercuri, and G. Bernardi The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy? Trends Pharmacol. Sci. 26 2005 341 344
67. J.H. Meyer, S. Kruger, A.A. Wilson, B.K. Christensen, V.S. Goulding, A. Schaffer, C. Minifie, S. Houle, D. Hussey, and S.H. Kennedy Lower dopamine transporter binding potential in striatum during depression Neuroreport 12 2001 4121 4125
68. S. Miachon, A. Berod, L. Leger, M. Chat, B. Hartman, and J.F. Pujol Identification of catecholamine cell bodies in the pons and pons-mesencephalon junction of the cat brain, using tyrosine hydroxylase and dopamine-beta- hydroxylase immunohistochemistry Brain Res. 305 1984 369 374
69. K.A. Michelsen, C. Schmitz, and H.W. Steinbusch The dorsal raphe nucleus-from silver stainings to a role in depression Brain Res. Rev. 55 2007 329 342
70. C. Miguelez, I. Fernandez-Aedo, M. Torrecilla, L. Grandoso, and L. Ugedo Alpha(2)-adrenoceptors mediate the acute inhibitory effect of fluoxetine on locus coeruleus noradrenergic neurons Neuropharmacology 56 2009 1068 1073
71. C. Miguelez, A. Aristieta, M.A. Cenci, and L. Ugedo The locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural study PLoS One 6 2011 e24679
72. C. Miguelez, L. Grandoso, and L. Ugedo Locus coeruleus and dorsal raphe neuron activity and response to acute antidepressant administration in a rat model of Parkinson's disease Int. J. Neuropsychopharmacol. 14 2011 187 200
73. M.J. Millan, A. Dekeyne, and A. Gobert Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo Neuropharmacology 37 1998 953 955
74. S. Navailles, A. Benazzouz, B. Bioulac, C. Gross, and P. De Deurwaerdere High-frequency stimulation of the subthalamic nucleus and L-3,4- dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease J. Neurosci. 30 2010 2356 2364
75. S. Navailles, B. Bioulac, C. Gross, and P. De Deurwaerdere Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease Neurobiol. Dis. 38 2010 136 143
76. M. Oz, L. Zhang, A. Rotondo, H. Sun, and M. Morales Direct activation by dopamine of recombinant human 5-HT1A receptors: comparison with human 5-HT2C and 5-HT3 receptors Synapse 50 2003 303 313
77. M.E. Page, and I. Lucki Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex Neuropsychopharmacology 27 2002 237 247
78. M.E. Page, M.J. Detke, A. Dalvi, L.G. Kirby, and I. Lucki Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test Psychopharmacology (Berl). 147 1999 162 167
79. M.E. Page, K. Brown, and I. Lucki Simultaneous analyses of the neurochemical and behavioral effects of the norepinephrine reuptake inhibitor reboxetine in a rat model of antidepressant action Psychopharmacology (Berl). 165 2003 194 201
80. E.P. Palvimaki, B.L. Roth, H. Majasuo, A. Laakso, M. Kuoppamaki, E. Syvalahti, and J. Hietala Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor Psychopharmacology (Berl). 126 1996 234 240
81. W.H. Pan, S.Y. Yang, and S.K. Lin Neurochemical interaction between dopaminergic and noradrenergic neurons in the medial prefrontal cortex Synapse 53 2004 44 52
82. G.I. Papakostas Dopaminergic-based pharmacotherapies for depression Eur. Neuropsychopharmacol. 16 2006 391 402
83. C. Peyron, J.M. Petit, C. Rampon, M. Jouvet, and P.H. Luppi Forebrain afferents to the rat dorsal raphe nucleus demonstrated by retrograde and anterograde tracing methods Neuroscience 82 1998 443 468
84. O.L. Pudovkina, and B.H. Westerink Functional role of alpha1-adrenoceptors in the locus coeruleus: a microdialysis study Brain Res. 1061 2005 50 56
85. M. Raiteri, R. Del Carmine, A. Bertollini, and G. Levi Effect of sympathomimetic amines on the synaptosomal transport of noradrenaline, dopamine and 5-hydroxytryptamine Eur. J. Pharmacol. 41 1977 133 143
86. G. Sacchetti, M. Bernini, A. Bianchetti, S. Parini, R.W. Invernizzi, and R. Samanin Studies on the acute and chronic effects of reboxetine on extracellular noradrenaline and other monoamines in the rat brain Br. J. Pharmacol. 128 1999 1332 1338
87. O. Schulte-Herbruggen, M.A. Vogt, H. Hortnagl, P. Gass, and R. Hellweg Pramipexole is active in depression tests and modulates monoaminergic transmission, but not brain levels of BDNF in mice Eur. J. Pharmacol. 677 2012 77 86
88. M. Suzuki, Y.L. Hurd, P. Sokoloff, J.C. Schwartz, and G. Sedvall D3 dopamine receptor mRNA is widely expressed in the human brain Brain Res. 779 1998 58 74
89. T.H. Svensson, B.S. Bunney, and G.K. Aghajanian Inhibition of both noradrenergic and serotonergic neurons in brain by the alpha-adrenergic agonist clonidine Brain Res. 92 1975 291 306
90. S.T. Szabo, and P. Blier Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons Eur. J. Neurosci. 13 2001 2077 2087
91. H. Tanaka, K. Kannari, T. Maeda, M. Tomiyama, T. Suda, and M. Matsunaga Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats Neuroreport 10 1999 631 634
92. M.E. Trulson, M.S. Cannon, and J.D. Raese Identification of dopamine-containing cell bodies in the dorsal and median raphe nuclei of the rat brain using tyrosine hydroxylase immunochemistry Brain Res. Bull. 15 1985 229 234
93. E. Vieta, and F. Colom Therapeutic options in treatment-resistant depression Ann. Med. 43 2011 512 530
94. J.T. Williams, G. Henderson, and R.A. North Characterization of alpha 2-adrenoceptors which increase potassium conductance in rat locus coeruleus neurones Neuroscience 14 1985 95 101
95. E.H. Wong, M.S. Sonders, S.G. Amara, P.M. Tinholt, M.F. Piercey, W.P. Hoffmann, D.K. Hyslop, S. Franklin, R.D. Porsolt, A. Bonsignori, N. Carfagna, and R.A. McArthur Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor Biol. Psychiatr. 47 2000 818 829
96. R.M. Woodward, M.M. Panicker, and R. Miledi Actions of dopamine and dopaminergic drugs on cloned serotonin receptors expressed in Xenopus oocytes Proc. Natl. Acad. Sci. U. S. A. 89 1992 4708 4712
97. H. Yamada, Y. Aimi, I. Nagatsu, K. Taki, M. Kudo, and R. Arai Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats Neurosci. Res. 59 2007 1 7
98. C. Yokoyama, H. Okamura, T. Nakajima, J. Taguchi, and Y. Ibata Autoradiographic distribution of [3H]YM-09151-2, a high-affinity and selective antagonist ligand for the dopamine D2 receptor group, in the rat brain and spinal cord J. Comp. Neurol. 344 1994 121 136
99. M. Yoshida, M. Shirouzu, M. Tanaka, K. Semba, and H.C. Fibiger Dopaminergic neurons in the nucleus raphe dorsalis innervate the prefrontal cortex in the rat: a combined retrograde tracing and immunohistochemical study using anti-dopamine serum Brain Res. 496 1989 373 376